Q32 Bio Inc (QTTB)
$29.76
Insights on Q32 Bio Inc
Decreasing Revenue
Revenue is down for the last 5 quarters, 802.0K → 354.0K (in $), with an average decrease of 14.0% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -35.04M → 1.02M (in $), with an average increase of 592.4% per quarter
Performance
- $29.50$30.06$29.76
0.87%
Downside
Day's Volatility :1.86%
Upside
1.0%
- $8.24$32.88$29.76
72.31%
Downside
52 Weeks Volatility :74.94%
Upside
9.49%
Returns
| Period | Q32 Bio Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 80.78% | 0.0% |
6 Months | 80.78% | 0.0% |
1 Year | 80.78% | 0.0% |
3 Years | 80.78% | -20.1% |
Highlights
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Q32 Bio Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Q32 Bio Inc | 21.27% | 80.78% | 80.78% | 80.78% | 80.78% |
 Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
 Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
 Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
 Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Q32 Bio Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Q32 Bio Inc | NA | $360.7M | 80.78% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Company Information
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Organization | Q32 Bio Inc |
Employees | 37 |
CEO | Ms. Jodie Pope Morrison |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$29.76
-1.13%
Keyarch Acquisition Corp
$29.76
-1.13%
Connexa Sports Technologies Inc
$29.76
-1.13%
Us Value Etf
$29.76
-1.13%
First Wave Biopharma Inc
$29.76
-1.13%
Global X Msci Next Emerging
$29.76
-1.13%
Fat Projects Acquisition Corp
$29.76
-1.13%
Ishares Intl Div Growth Etf
$29.76
-1.13%
Corsair Gaming, Inc.
$29.76
-1.13%